![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.473, 2005-01, pp. : 5-5
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Gemfibrozil warranted for primary prevention of CHD
Inpharma, Vol. 1, Iss. 1478, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Rethink use of statins for primary prevention in CHD?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 269, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Raloxifene warranted for fracture prevention in Sweden
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 469, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
HRT solely for prevention of CHD in postmenopausal women
Inpharma, Vol. 1, Iss. 1302, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Stress testing not worthwhile for targeting CHD prevention
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 604, 2010-01 ,pp. :